



NEWS RELEASE

# SELLAS Life Sciences to Host Shareholder Update Call on June 3rd

5/11/2021

NEW YORK, May 11, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that it will host a Shareholder Update Call on Thursday, June 3, 2021 at 8:30 a.m. ET.

The call will be facilitated by SELLAS' President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update.

---

Event: Shareholder Update Call  
Date: Thursday, June 3, 2021  
Time: 8:30 a.m. ET  
Live Call: 1-877-407-9716 (U.S. Toll Free) or 1-201-493-6779 (International)  
Webcast: <https://www.sellaslifesciences.com/investors/events-and-presentations>

For interested individuals unable to join the conference call, a replay of the call will be available through June 17, 2021, at 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13719788. The online archive of the webcast will be available at <https://www.sellaslifesciences.com/investors/events-and-presentations> after the conclusion of the call.

About SELLAS Life Sciences Group, Inc.

SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS' lead product candidate, galinpepimut-S (GPS), is licensed from Memorial

Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS' second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes TNBC patients, following the standard of care.

For more information on SELLAS, please visit [www.sellaslifesciences.com](http://www.sellaslifesciences.com).

#### Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are "forward-looking statements," including those relating to future events. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various important factors. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.

For more information, please contact:

#### Investor Contacts

Valter Pinto / Allison Soss

KCSA Strategic Communications

Email: [SELLAS@kcsa.com](mailto:SELLAS@kcsa.com)

Phone: 914.907.2675 / 215.272.2707

#### Media Contacts

Caitlin Kasunich / Raquel Cona

KCSA Strategic Communications

Email: [SELLAS@kcsa.com](mailto:SELLAS@kcsa.com)

Phone: 212.896.1241 / 212.896.1276

Source: SELLAS Life Sciences Group, Inc.